Pelaia Girolamo, Renda Teresa, Romeo Pasquale, Busceti Maria Teresa, Maselli Rosario
Department of Experimental and Clinical Medicine, Section of Respiratory Diseases, University Magna Graecia of Catanzaro, Italy,
Ther Adv Respir Dis. 2008 Dec;2(6):409-21. doi: 10.1177/1753465808100431.
Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high-affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include relevant improvements in respiratory symptoms and quality of life, paralleled by a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma, inadequately controlled by high doses of standard inhaled treatments.
奥马珠单抗是一种人源化单克隆抗IgE抗体，最近被批准用于治疗重度过敏性哮喘。该药物通过与血清IgE结合来抑制过敏反应，从而阻止其与细胞IgE受体相互作用。奥马珠单抗还能够下调炎症细胞上高亲和力IgE受体的表达，以及血液和诱导痰中嗜酸性粒细胞的数量。奥马珠单抗的临床效果包括呼吸症状和生活质量的相关改善，同时哮喘急性加重、急诊就诊次数以及全身用皮质类固醇和急救支气管扩张剂的使用显著减少。奥马珠单抗耐受性相对良好，仅很少诱发过敏反应。因此，对于高剂量标准吸入治疗控制不佳的重度持续性过敏性哮喘患者，该药物是一种有效的附加治疗选择。
